Dossier assessment

Lixisenatide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

Status
Status: Commission completed
Project no.
A13-11
Last updated

Report documents

  1. Extract of dossier assessment

    Lixisenatide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

    published on
    Document type
    PDF document, 429 kB, EN, not accessible
  2. Dossier assessment

    Lixisenatide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

    published on
    Document type
    PDF document, 726 kB, DE, not accessible

Press releases

Added benefit of lixisenatide is not proven

Drug manufacturer's dossier did not contain suitable data for any therapeutic indication

Additional information

Federal Joint Committee (G-BA)

2013-09-05 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A13-11
Commission
Commission awarded on 18.03.2013 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Digestion, metabolism and hormones
Note

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form